دورية أكاديمية
Targeting triple-negative breast cancer: A clinical perspective.
| العنوان: | Targeting triple-negative breast cancer: A clinical perspective. |
|---|---|
| المؤلفون: | Popovic LS; Department of Medical Oncology, Oncology Institute of Vojvodina, Sremska Kamenica, Serbia.; Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia., Matovina-Brko G; Department of Medical Oncology, Oncology Institute of Vojvodina, Sremska Kamenica, Serbia., Popovic M; Department of Medical Oncology, Oncology Institute of Vojvodina, Sremska Kamenica, Serbia.; Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia., Punie K; Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium., Cvetanovic A; Department for Oncology, Medical Faculty Nis, University of Nis, Nis, Serbia.; Clinic of Oncology, Clinical Centre Nis, Nis, Serbia., Lambertini M; Department of Internal Medicine and Medical Sciences (DiMI), School of Medicine, University of Genova, Genova, Italy.; Department of Medical Oncology, U.O.C Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy. |
| المصدر: | Oncology research [Oncol Res] 2023 May 24; Vol. 31 (3), pp. 221-238. Date of Electronic Publication: 2023 May 24 (Print Publication: 2023). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Tech Science Press Country of Publication: United States NLM ID: 9208097 Publication Model: eCollection Cited Medium: Internet ISSN: 1555-3906 (Electronic) Linking ISSN: 09650407 NLM ISO Abbreviation: Oncol Res Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2021- : Henderson, NV : Tech Science Press Original Publication: New York : Pergamon Press, c1992- |
| مواضيع طبية MeSH: | Triple Negative Breast Neoplasms*/genetics , Triple Negative Breast Neoplasms*/therapy, Humans ; Immunotherapy ; Immunomodulation ; Lymphocytes, Tumor-Infiltrating |
| مستخلص: | Triple-negative breast cancer (TNBC) is a disease with often an aggressive course and a poor prognosis compared to other subtypes of breast cancer. TNBC accounts for approximately 10%-15% of all diagnosed breast cancer cases and represents a high unmet need in the field. Up to just a few years ago, chemotherapy was the only systemic treatment option for this subtype (1). To date, TNBC is considered a heterogeneous disease. One of the existing classifications is based on the analysis of mRNA expression in 587 TNBC cases, in which Lehman et al. proposed six subtypes of TNBC as follows: two basal-like (BL1 and BL2) subtypes, a mesenchymal (M) subtype, a mesenchymal stem-like (MSL) subtype, an immunomodulatory (IM) subtype, and a luminal androgen receptor (LAR) subtype (2). Later studies have demonstrated that the IM and MSL subtypes do not correlate with independent subtypes but reflect background expression by dense infiltration of tumor-infiltrating lymphocytes (TILs) or stromal cells. According to this finding, the classification of TNBC has been revised into the following four subtypes: basal 1, basal 2, LAR, and mesenchymal subtypes (3). Over the last years, several new strategies have been investigated for the treatment of patients with TNBC. Among them, immunotherapy, antibody drug conjugates, new chemotherapy agents, and targeted therapy have been and are currently being developed. The present article aims to provide an updated overview on the different treatment options that are now available or are still under investigation for patients with TNBC. Competing Interests: Lazar S. Popovic: Speaking fee and/or advisory board: Roche, MSD, BMS, Astra Zeneca, Pfizer, Novartis, Gilead, Sandoz, Takeda, Astellas, Janssen, Sanofi, Abbvie, Merck, Lilly (all outside of submitted work). Gorana Matovina Brko: Speaking fee and travel support: Roche, Pfizer, Novartis, Astellas, Janssen, Sanofi, Merck (all outside of submitted work). Maja Popovic Speaking fee and travel support: Roche, BMS, Pfizer, Merck, Takeda, Astellas, Janssen (all outside of submitted work). Kevin Punie: Travel support from AstraZeneca, Pfizer, PharmaMar and Roche (outside the submitted work). His institution received honoraria for advisory/consultancy roles for AstraZeneca, Eli Lilly, Gilead Sciences, Novartis, Pfizer, Pierre Fabre, Roche, Teva and Vifor Pharma, Speaker fees for Eli Lilly, Medscape, MSD, Mundi Pharma, Novartis, Pfizer and Roche, and Research funding from MSD and Sanofi (all outside the submitted work). Ana Cvetanovic: Speaking fee and/or advisory board: Roche, MSD, Astra Zeneca, Pfizer, Novartis, Lilly (all outside of submitted work). Matteo Lambertini acted as a consultant for Roche, Pfizer, Lilly, MSD, Seagen, Gilead, AstraZeneca and Novartis, and received honoraria from Sandoz, Takeda, Ipsen, Roche, Lilly, Pfizer and Novartis (all outside the submitted work). (© 2023 Popovic et al.) |
| References: | Target Oncol. 2021 May;16(3):255-282. (PMID: 33710534) Lancet Oncol. 2016 Jun;17(6):e254-e262. (PMID: 27299281) Cancer Discov. 2020 Feb;10(2):198-213. (PMID: 31806627) Nat Rev Clin Oncol. 2018 May;15(5):273-291. (PMID: 29508857) Lancet Oncol. 2021 Apr;22(4):499-511. (PMID: 33676601) ESMO Open. 2017 Jun 23;2(2):e000165. (PMID: 28761743) Ann Oncol. 2015 Feb;26(2):259-71. (PMID: 25214542) Ann Oncol. 2019 Aug 1;30(8):1289-1297. (PMID: 31147675) Ann Oncol. 2021 Dec;32(12):1475-1495. (PMID: 34678411) N Engl J Med. 2018 Nov 29;379(22):2108-2121. (PMID: 30345906) N Engl J Med. 2019 May 16;380(20):1929-1940. (PMID: 31091374) Ann Oncol. 2018 Jul 1;29(7):1497-1508. (PMID: 29873695) JCO Precis Oncol. 2021 Nov;5:1297-1311. (PMID: 34994634) Lancet. 2019 Apr 6;393(10179):1440-1452. (PMID: 30739743) World J Stem Cells. 2021 Jun 26;13(6):503-520. (PMID: 34249225) Ann Oncol. 2021 Sep;32(9):1148-1156. (PMID: 34116144) Ann Oncol. 2022 Apr;33(4):384-394. (PMID: 35093516) JAMA Oncol. 2020 May 1;6(5):676-684. (PMID: 32053137) Lancet. 2012 Feb 4;379(9814):432-44. (PMID: 22152853) Lancet. 2020 Dec 5;396(10265):1817-1828. (PMID: 33278935) Clin Cancer Res. 2021 Jul 15;27(14):3896-3904. (PMID: 33602685) Breast Dis. 2010;32(1-2):25-33. (PMID: 21778580) Nat Commun. 2016 May 10;7:11479. (PMID: 27161491) NPJ Breast Cancer. 2020 Sep 25;6:47. (PMID: 33062889) J Clin Oncol. 2016 Jul 20;34(21):2460-7. (PMID: 27138582) Lancet Oncol. 2018 Apr;19(4):497-509. (PMID: 29501363) Ther Adv Med Oncol. 2020 Aug 17;12:1758835920940928. (PMID: 32874208) Expert Opin Biol Ther. 2022 Mar;22(3):345-348. (PMID: 34930070) Clin Cancer Res. 2022 Feb 15;28(4):629-636. (PMID: 34887261) Lancet Oncol. 2020 Feb;21(2):271-282. (PMID: 31838007) N Engl J Med. 2016 Jul 7;375(1):23-34. (PMID: 27406347) JAMA Oncol. 2020 Sep 1;6(9):1390-1396. (PMID: 32789480) Ann Oncol. 2022 Nov;33(11):1149-1158. (PMID: 35961599) Nature. 2012 Oct 4;490(7418):61-70. (PMID: 23000897) N Engl J Med. 2022 Jul 21;387(3):217-226. (PMID: 35857659) PLoS One. 2016 Jun 16;11(6):e0157368. (PMID: 27310713) Ann Oncol. 2016 May;27(5):812-8. (PMID: 27052658) Lancet Oncol. 2020 Jan;21(1):44-59. (PMID: 31786121) ESMO Open. 2020 Nov;5(6):e001112. (PMID: 33214229) JAMA Oncol. 2019 Mar 1;5(3):334-342. (PMID: 30347025) Ann Oncol. 2022 Mar;33(3):347-349. (PMID: 34861375) Ann Oncol. 2019 Jul 1;30(7):1051-1060. (PMID: 31050709) Drugs Context. 2018 Feb 12;7:212520. (PMID: 29456568) Lancet Oncol. 2019 Nov;20(11):1587-1601. (PMID: 31575503) Lancet. 2020 Oct 10;396(10257):1090-1100. (PMID: 32966830) NPJ Breast Cancer. 2019 Oct 29;5:37. (PMID: 31700993) J Natl Compr Canc Netw. 2022 Jun;20(6):691-722. (PMID: 35714673) N Engl J Med. 2016 Nov 10;375(19):1823-1833. (PMID: 27718847) Ann Oncol. 2020 May;31(5):569-581. (PMID: 32278621) N Engl J Med. 2022 Mar 24;386(12):1143-1154. (PMID: 35320644) Ann Oncol. 2019 Mar 1;30(3):397-404. (PMID: 30475950) Cancer Immunol Res. 2014 Apr;2(4):361-70. (PMID: 24764583) Ann Oncol. 2022 May;33(5):534-543. (PMID: 35182721) Ann Oncol. 2022 Dec;33(12):1250-1268. (PMID: 36228963) Clin Cancer Res. 2013 Oct 1;19(19):5505-12. (PMID: 23965901) N Engl J Med. 2018 Feb 22;378(8):731-739. (PMID: 29466156) N Engl J Med. 2010 Nov 11;363(20):1938-48. (PMID: 21067385) Oncologist. 2021 Oct;26(10):827-834. (PMID: 34176192) Exp Mol Pathol. 2013 Feb;94(1):73-8. (PMID: 23031786) J Clin Oncol. 2020 Dec 20;38(36):4274-4282. (PMID: 33119476) Clin Cancer Res. 2020 May 1;26(9):2111-2123. (PMID: 31822498) N Engl J Med. 2022 Jul 7;387(1):9-20. (PMID: 35665782) J Clin Oncol. 2021 Aug 10;39(23):2539-2551. (PMID: 34092112) Nat Med. 2021 Feb;27(2):250-255. (PMID: 33462450) N Engl J Med. 2019 Feb 21;380(8):741-751. (PMID: 30786188) N Engl J Med. 2017 Aug 10;377(6):523-533. (PMID: 28578601) Ann Oncol. 2019 Aug 1;30(8):1279-1288. (PMID: 31095287) Mol Cancer. 2010 Sep 21;9:253. (PMID: 20858281) J Clin Oncol. 2018 Mar 20;36(9):884-890. (PMID: 29373071) Ann Oncol. 2021 Aug;32(8):994-1004. (PMID: 34219000) Lancet Oncol. 2020 Oct;21(10):1269-1282. (PMID: 32861273) N Engl J Med. 2015 Jun 25;372(26):2521-32. (PMID: 25891173) World J Clin Oncol. 2022 Jan 24;13(1):28-38. (PMID: 35116230) JAMA Oncol. 2021 Feb 1;7(2):271-278. (PMID: 33377972) Nat Rev Clin Oncol. 2018 Dec;15(12):731-747. (PMID: 30333516) N Engl J Med. 2017 Jun 1;376(22):2147-2159. (PMID: 28564564) N Engl J Med. 2020 Feb 27;382(9):810-821. (PMID: 32101663) J Clin Oncol. 2020 Feb 10;38(5):423-433. (PMID: 31841354) JAMA Oncol. 2019 Jan 1;5(1):74-82. (PMID: 30242306) Nat Rev Clin Oncol. 2016 Apr;13(4):228-41. (PMID: 26667975) Ann Oncol. 2019 Mar 1;30(3):405-411. (PMID: 30475947) N Engl J Med. 2021 Apr 22;384(16):1529-1541. (PMID: 33882206) J Clin Oncol. 2017 Jul 1;35(19):2141-2148. (PMID: 28291390) JAMA. 2021 Jan 5;325(1):50-58. (PMID: 33300950) N Engl J Med. 2021 Jun 24;384(25):2394-2405. (PMID: 34081848) N Engl J Med. 2018 Aug 23;379(8):753-763. (PMID: 30110579) J Clin Invest. 2011 Jul;121(7):2750-67. (PMID: 21633166) J Natl Cancer Inst. 2021 Nov 29;113(12):1733-1743. (PMID: 34097070) Lancet Oncol. 2017 Oct;18(10):1360-1372. (PMID: 28800861) Expert Opin Investig Drugs. 2022 Jun;31(6):567-591. (PMID: 35240902) |
| فهرسة مساهمة: | Keywords: Antibody-drug conjugates; Immunotherapy; Target therapy; Triple-negative breast cancer |
| تواريخ الأحداث: | Date Created: 20230612 Date Completed: 20230613 Latest Revision: 20230613 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC10229315 |
| DOI: | 10.32604/or.2023.028525 |
| PMID: | 37305385 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1555-3906 |
|---|---|
| DOI: | 10.32604/or.2023.028525 |